USPTO serial 79358612
NUACRES
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- May 6, 2025
- Examiner
- REINHART, MEGHAN M
- Law office
- FILE REPOSITORY (FRANCONIA)
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with NUACRES?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Chemical or biological substances in the nature of Oligo- and poly-nucleotide arrays for scientific and medical research and reagents for scientific purposes; Chemical or biological substances, namely, molecular constructs made of DNA or RNA to serve as reagents for research in the field of diagnostics; Chemical or biological molecular constructs made of DNA or RNA for scientific or medical research use; Chemicals and chemical preparations for use in agriculture, horticulture and forestry except fungicides, herbicides, insecticides and parasiticides | ACTIVE | — |
| 005 | Medical and veterinary preparations for the treatment of neoplastic pathologies and infectious diseases; pharmaceuticals, namely, vaccines; biomedical pharmaceutical products for the treatment of neoplastic pathologies and infectious diseases; clinical diagnostic reagents for medical use; therapeutical agent substances in the nature of oligo- and poly-nucleotides and nucleic acid antibodies (aptamers); Prophylactical agent substances in the nature of infection prophylactic agents and cancer prophylactic agents; pharmaceutical products, particularly for the field of oncology and infectiology all in the nature of pharmaceutical products for the prevention and treatment of cancer and infectious diseases; biomedical products based on cytological research substances all in the nature of oligo- and poly-nucleotides and nucleic acid antibodies (aptamers); pharmaceuticals, particularly for the use in algorithm supported medical treatment all in the nature of pharmaceuticals for treating of infectious diseases and cancer; chemical or biological substances in the nature of oligo- and poly-nucleotides and nucleotids and nucleic acid antibodies (aptamers) and reagents as part of medical and veterinary preparations; chemical or biological substances in the nature of oligo- and poly-nucleotides and nucleic acid antibodies all for the treatment of cancer and infectious diseases and reagents for medical and veterinary use; agonists for medical and veterinary use; TLR agonists for medical and veterinary use; agonists as part of medical and veterinary preparations; TLR agonists as part of medical and veterinary preparations | ACTIVE | — |
| 042 | Technical services relating to pharmaceutical and medical preparations, pharmaceuticals and drugs, namely, technical research in the field of using computers to diagnose disease and health conditions; provision of information relating to medical and veterinary research and development, particularly in the field of oncology and infectiology; providing an on-line searchable database in the fields of medical and veterinary research and development, particularly in the field of oncology and infectiology; research and development for the pharmaceutical industry, particularly in the field of oncology and infectiology; biomedical research services; research and development services in the field of oncology; research and development services in the field of infectiology; research and development of biomolecules, cells and cellular products for medical use; research and development of biomedical products, particularly therapeutical and prophylactic substances for medical use in the field of oncology and infectiology; research and development in the field of clinical treatment algorithms; medical laboratory services; computer diagnostic services, particularly based on clinical treatment algorithms; computer diagnostic services, particularly in the field of oncology; computer diagnostic services, particularly in the field of infectiology; development of diagnostic apparatus for computer aided medical treatment | ACTIVE | — |
| 044 | Medical treatments, particularly in the field of oncology and infectiology; medical analysis services related to the treatment of patients, particularly in the field of oncology and infectiology; medical services in connection with the treatment of cancer; medical testing in connection with the diagnosis and treatment of diseases, particularly in the field of oncology and infectiology; medical testing for diagnostic or treatment purposes, particularly in the field of oncology and infectiology; medical treatments based on clinical treatment algorithms, particularly in the field of oncology and infectiology; performance of medical tests related to the diagnosis and treatment of cancer; medical examinations for the diagnosis or treatment of cancer; medical treatments of cancer based on clinical treatment algorithms; medical equipment rental, particularly for computer aided treatments; medical services; pharmaceutical services, namely, monitoring of drug therapy used for cancer and infectious diseases for medical treatment and diagnosis purposes; computer-assisted medical assessment and diagnostical services | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Burghardt Wittig
- Other trademarks owned by Nucleic Acids to the Rescue GmbH
- Other trademarks owned by Nucleic Acids to the Rescue GmbH
- Other trademarks owned by Nucleic Acids to the Rescue GmbH
- Other trademarks owned by Gentechnologiestiftung -
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 042
- Other trademarks in Class 044
- Similar marks named NUACRES
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jul 23, 2026 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Dec 11, 2025 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Nov 26, 2025 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Nov 26, 2025 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Aug 6, 2025 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| May 6, 2025 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| May 6, 2025 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Mar 19, 2025 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Mar 19, 2025 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Mar 19, 2025 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Mar 19, 2025 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Mar 19, 2025 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Mar 18, 2025 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Mar 12, 2025 | NPUB | NOTICE OF PUBLICATION | — |
| Feb 25, 2025 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Feb 25, 2025 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Jun 30, 2024 | OPNX | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB | — |
| Jun 21, 2024 | CHLD | CHANGE OF OWNER RECEIVED FROM IB | — |
| Jun 14, 2024 | CHLD | CHANGE OF OWNER RECEIVED FROM IB | — |
| Jun 7, 2024 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Jun 7, 2024 | OPNR | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB | — |
| Apr 29, 2024 | ZZZX | PREVIOUS ALLOWANCE COUNT WITHDRAWN | — |
| Apr 19, 2024 | PBSR | WITHDRAWN FROM PUB - SENIOR ATTORNEY REQUEST | — |
| Apr 17, 2024 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Mar 7, 2024 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Mar 7, 2024 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Mar 7, 2024 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Oct 17, 2023 | RFNT | REFUSAL PROCESSED BY IB | — |
| Sep 25, 2023 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Sep 25, 2023 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Sep 7, 2023 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Sep 6, 2023 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Aug 22, 2023 | DOCK | ASSIGNED TO EXAMINER | — |
| Dec 31, 2022 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Dec 27, 2022 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Dec 23, 2022 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |